In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Audentes Therapeutics Inc. (NASDAQ:BOLD) reported that Flynn James E  has picked up 1,214,423 of common stock as of 2017-04-26.

The acquisition brings the aggregate amount owned by Flynn James E to a total of 1,214,423 representing less than 4.38% stake in the company.

For those not familiar with the company, Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

A glance at Audentes Therapeutics Inc. (NASDAQ:BOLD)’s key stats reveals a current market capitalization of 409.36 Million based on 26.93 Million shares outstanding and a price at last close of $14.98 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-07-25, Woiwode picked up 219 at a purchase price of $15.00. This brings their total holding to 11,308 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Audentes Therapeutics Inc. (NASDAQ:BOLD) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.